Covaxin capacity scaled up to 500 million doses a year: Bharat Biotech

Vaccine effective against all emerging coronavirus variants, says study

Hyderabad-based vaccine maker Bharat Biotech in April expanded its Covaxin-manufacturing capacity to 500 million doses a year, the company said on Sunday.

It supplied 20 million doses to the “national roll-out” in April.

In a tweet, Suchitra Ella, joint managing director of Bharat Biotech, said: “To our supporters and critics, ever since the start of the pandemic, team Bharat Biotech has been diligently developing Covaxin and scaling up manufacturing capacities to meet global and public health requirements.”

In the same tweet, Ella also pointed out that Covaxin neutralises key emerging strains of the Sars-CoV-2 virus, including the double mutant B.1.617